125 related articles for article (PubMed ID: 3326816)
41. p16 immunoreactivity may assist in the distinction between endometrial and endocervical adenocarcinoma.
McCluggage WG; Jenkins D
Int J Gynecol Pathol; 2003 Jul; 22(3):231-5. PubMed ID: 12819388
[TBL] [Abstract][Full Text] [Related]
42. Thyroid transcription factor-1 expression in endometrial and endocervical adenocarcinomas.
Siami K; McCluggage WG; Ordonez NG; Euscher ED; Malpica A; Sneige N; Silva EG; Deavers MT
Am J Surg Pathol; 2007 Nov; 31(11):1759-63. PubMed ID: 18059234
[TBL] [Abstract][Full Text] [Related]
43. Immunohistochemical localizations of CA 125, carcinoembryonic antigen, and CA 19-9 in normal and neoplastic glandular cells of the uterine cervix.
Nanbu Y; Fujii S; Konishi I; Nonogaki H; Mori T
Cancer; 1988 Dec; 62(12):2580-8. PubMed ID: 3191457
[TBL] [Abstract][Full Text] [Related]
44. [Value of ER, VIM, CEA and p16 detection in the diagnosis and differential diagnosis of primary endocervical and endometrial adenocarcinomas].
Hu WW; Tao JH; Li GM; Xu X; Yang XM
Nan Fang Yi Ke Da Xue Xue Bao; 2010 Mar; 30(3):526-8, 531. PubMed ID: 20335127
[TBL] [Abstract][Full Text] [Related]
45. Distinguishing between primary endocervical and endometrial adenocarcinomas: is a 2-marker (Vim/CEA) panel enough?
Liao CL; Hsu JD; Lee MY; Kok LF; Li YJ; Wang PH; Yao CC; Han CP
Virchows Arch; 2010 Apr; 456(4):377-86. PubMed ID: 20221633
[TBL] [Abstract][Full Text] [Related]
46. Adenocarcinoma in situ of the cervix. Clinicopathologic observations of 11 cases.
Tobón H; Dave H
Int J Gynecol Pathol; 1988; 7(2):139-51. PubMed ID: 3294196
[TBL] [Abstract][Full Text] [Related]
47. Intestinal-type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial enteric immunophenotype with consistent expression of CDX2.
McCluggage WG; Shah R; Connolly LE; McBride HA
Int J Gynecol Pathol; 2008 Jan; 27(1):92-100. PubMed ID: 18156982
[TBL] [Abstract][Full Text] [Related]
48. Immunohistochemical staining for Ki-67 antigen, carcinoembryonic antigen, and p53 in the differential diagnosis of glandular lesions of the cervix.
Cina SJ; Richardson MS; Austin RM; Kurman RJ
Mod Pathol; 1997 Mar; 10(3):176-80. PubMed ID: 9071723
[TBL] [Abstract][Full Text] [Related]
49. The distinction of adenocarcinoma from malignant mesothelioma in cell blocks of effusions: the role of routine mucin histochemistry and immunohistochemical assessment of carcinoembryonic antigen, keratin proteins, epithelial membrane antigen, and milk fat globule-derived antigen.
Cibas ES; Corson JM; Pinkus GS
Hum Pathol; 1987 Jan; 18(1):67-74. PubMed ID: 2434407
[TBL] [Abstract][Full Text] [Related]
50. Gastric-type adenocarcinoma in situ of uterine cervix: cytological and histopathological features of two cases.
Yuan CT; Lin MC; Kuo KT; Wang TH; Mao TL
Virchows Arch; 2016 Sep; 469(3):351-6. PubMed ID: 27334141
[TBL] [Abstract][Full Text] [Related]
51. Observations of high iron diamine-alcian blue stain in uterine cervical glandular lesions.
Kase H; Kodama S; Tanaka K
Gynecol Obstet Invest; 1999; 48(1):56-60. PubMed ID: 10394094
[TBL] [Abstract][Full Text] [Related]
52. Ancillary p16(INK4a) adds no meaningful value to the performance of ER/PR/Vim/CEA panel in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray study.
Yao CC; Kok LF; Lee MY; Wang PH; Wu TS; Tyan YS; Cheng YW; Kung MF; Han CP
Arch Gynecol Obstet; 2009 Sep; 280(3):405-13. PubMed ID: 19153755
[TBL] [Abstract][Full Text] [Related]
53. Immunoprofile of cervical and endometrial adenocarcinomas using a tissue microarray.
Alkushi A; Irving J; Hsu F; Dupuis B; Liu CL; Rijn M; Gilks CB
Virchows Arch; 2003 Mar; 442(3):271-7. PubMed ID: 12647218
[TBL] [Abstract][Full Text] [Related]
54. Morphofunctional findings in adenocarcinoma of endometrium.
Eusebi V; Pelusi G; Bondi A; Morichelli MP; Ceccarelli C; Cavallina R; Mancini AM
Tumori; 1984 Jun; 70(3):291-5. PubMed ID: 6204431
[TBL] [Abstract][Full Text] [Related]
55. Adenoma malignum (minimal deviation adenocarcinoma) of the uterine cervix. A clinicopathological and immunohistochemical analysis of 26 cases.
Gilks CB; Young RH; Aguirre P; DeLellis RA; Scully RE
Am J Surg Pathol; 1989 Sep; 13(9):717-29. PubMed ID: 2764221
[TBL] [Abstract][Full Text] [Related]
56. Architectural overlap between benign endocervix and pattern-A endocervical adenocarcinoma: Are all pattern-A tumors invasive?
Douglas G; Howitt BE; Schoolmeester JK; Schwartz L; Kos Z; Islam S; Djordjevic B; Parra-Herran C
Pathol Res Pract; 2017 Jul; 213(7):799-803. PubMed ID: 28554747
[TBL] [Abstract][Full Text] [Related]
57. An immunohistochemical study of difference between cervical and endometrial adenocarcinomas of the uterus--using monoclonal antibodies of vimentin and cytokeratin.
Jinnouchi H
Fukushima J Med Sci; 1987 Dec; 33(2):85-108. PubMed ID: 2471680
[No Abstract] [Full Text] [Related]
58. Enteric differentiation in endometrial adenocarcinomas: a mucin histochemical study.
McCluggage WG; Roberts N; Bharucha H
Int J Gynecol Pathol; 1995 Jul; 14(3):250-4. PubMed ID: 8600077
[TBL] [Abstract][Full Text] [Related]
59. Endocervical cancer is associated with an increase in the ligands and receptors for transforming growth factor-beta and a contrasting decrease in p27(Kip1).
Farley J; Gray K; Nycum L; Prentice M; Birrer MJ; Jakowlew SB
Gynecol Oncol; 2000 Aug; 78(2):113-22. PubMed ID: 10926789
[TBL] [Abstract][Full Text] [Related]
60. [The relationship between carcinoembryonic antigen (CEA) expression and histogenesis of gastric cancer (application of immunohistochemical and mucin histochemical techniques)].
Wu JF
Zhonghua Zhong Liu Za Zhi; 1992 Jan; 14(1):13-6. PubMed ID: 1327687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
